Industry Center - Biotechnology
|Contact Information |
|Address: ||2000 Hamilton St., Ste. 204 |
Philadelphia, PA 19130
|Phone: ||215-241-9760 |
|Fax: ||215-241-9684 |
|Key People |
|• ||Chairman and CEO: John K. A. Prendergast |
|• ||CFO and Director: Richard P. (Rich) Rainey |
|AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax). |
AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
AVAX Technologies, Inc. Files Form 10 With SEC
Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST
PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC"). Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company. The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.
The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA. The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.
The Company's AC Vaccine platform is a therapeutic cancer vaccine.
Certain statements in this release are "forward-looking" statements. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.